William Blair Believes AveXis Inc (NASDAQ: AVXS) Won’t Stop Here

By Ryan Adsit

William Blair analyst Raju Prasad maintained a Buy rating on AveXis Inc (NASDAQ: AVXS) today. The company’s shares opened today at $133.80, close to its 52-week high of $138.46.

According to TipRanks.com, Prasad is a 3-star analyst with an average return of 13.8% and a 66.7% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Audentes Therapeutics, and Spark Therapeutics.

Currently, the analyst consensus on AveXis Inc is Strong Buy and the average price target is $138.75, representing a 3.7% upside.

In a report issued on February 28, Mizuho Securities also maintained a Buy rating on the stock with a $147 price target.

The company has a one-year high of $138.46 and a one-year low of $65.23. Currently, AveXis Inc has an average volume of 533.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

AveXis, Inc. operates as a clinical-stage gene therapy company that engages in the research and development of technology specifically for neurological genetic disease treatment. Its proprietary gene therapy candidate, AVXS-101 has been granted orphan drug designation for the treatment of all types of spinal muscular atrophy and fast track designation for the treatment of spinal muscular atrophy type 1. The company was founded by John D. Harkey, Jr. in 2010 and is headquartered in Chicago, IL.